DGAP-News

Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM) - Seite 3

resulting primarily from Novavax AB's expenses and higher professional fees.

As of December 31, 2013, the company had $133.1 million in cash and cash
equivalents and investments compared to $50.3 million as of December 31, 2012.
Net cash used in operating activities for 2013 was $45.4 million compared to
$18.2 million for 2012. The increase in cash usage from the prior year was
primarily due to higher research and development spending, including the
company's RSV and pandemic (H7N9) influenza clinical trials, as well as
increased employee-related costs.

Conference Call

Novavax management will host its quarterly conference call today at 4:30 p.m.
EDT. The dial-in number for the conference call is 1 [phone] (U.S. or
Canada) or 1 [phone] (international). A webcast of the conference call
can also be accessed via a link on the home page of the Novavax website
(novavax.com) or through the 'Investor Info'/'Events' tab on the Novavax
website.

A replay of the conference call will be available starting at 7:30 p.m. on
March 10, 2014 until midnight May 1, 2014. To access the replay by telephone,
dial 1 [phone] (domestic) or 1 [phone] (international) and use
passcode 2459615. The replay will also be available as a webcast and can be
found on the 'Investor Info'/'Events' on the Novavax website.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using innovative proprietary recombinant protein
nanoparticle vaccine technology, the company produces vaccine candidates to
efficiently and effectively respond to both known and newly emergent diseases.
Novavax is involved in several international partnerships, including
collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea
and PATH, and recently acquired Isconova AB, a leading vaccine adjuvant company
located in Sweden. Together, Novavax' network supports its global
commercialization strategy to create real and lasting change in the
biopharmaceutical and vaccinology fields. Additional information about Novavax
is available on the company's website, novavax.com.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development
of its vaccine and adjuvant products are forward-looking statements. Novavax
cautions that these forward looking statements are subject to numerous risks
and uncertainties, which could cause actual results to differ materially from
those expressed or implied by such statements. These risks and uncertainties